CUSIP: 14888D208
Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Stock
-
Total 13F shares
-
7,902,121
-
Share change
-
-1,647,672
-
Total reported value
-
$14,060,954
-
Put/Call ratio
-
4%
-
Price per share
-
$1.78
-
Number of holders
-
37
-
Value change
-
-$492,010
-
Number of buys
-
10
-
Number of sells
-
24
Quarterly Holders Quick Answers
What is CUSIP 14888D208?
CUSIP 14888D208 identifies CBIO - GYRE THERAPEUTICS INC COM - Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2022
-
Previous quarter:
Q1 2022
Recent filing periods for CUSIP 14888D208:
Institutional Holders of GYRE THERAPEUTICS INC COM - Stock (CBIO) as of Q2 2022
As of 30 Jun 2022,
GYRE THERAPEUTICS INC COM - Stock (CBIO) was held by
37 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,902,121 shares.
The largest 10 holders included
Nantahala Capital Management, LLC, VANGUARD GROUP INC, Madison Avenue Partners, LP, RENAISSANCE TECHNOLOGIES LLC, MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, Bank of New York Mellon Corp, BlackRock Inc., GOLDMAN SACHS GROUP INC, and Kynam Capital Management, LP.
This page lists
37
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.